Infectious Disease · AntiparasiticRegulatory Approvalcommercialnear-term

Glenmark's Atovaquone ANDA209685 Receives Abbreviated Approval

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 6/22/2026, 6:32:53 PM

Assessment confidence: 66% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

The abbreviated approval of Glenmark's Atovaquone presents a significant shift in the competitive landscape for this therapeutic area. Pharma companies with Atovaquone-related products must evaluate their pricing strategies and market positioning in response to Glenmark's entry. Regulatory context from FDA (FDA AP — ATOVAQUONE (SUPPL)) supports the near-term read. Assessment grounded in 22 ranked evidence items (10 high-relevance).

Strategic Assessment

Portfolio teams should assess the impact of Glenmark's entry on their own Atovaquone-related products and consider pricing strategies. The strongest clinical anchor is Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopic Dermatitis (ClinicalTrials.gov), moderate corpus alignment. In Infectious Disease · Antiparasitic, 6 regulatory and 5 competitive items passed relevance filtering for Atovaquone.

Competitive Pressure

The most relevant competitive pressure comes from Merck's ENFLONSIA Approved in EU for RSV Prevention in Infants (Humanexa Signals) — sponsor/company relevance (merck). Secondary pressure from Roche receives CE mark for new blood test to detect Alzheimer's pathology: Elecsys® plasma phosphorylated-tau 217 (pTau217). This approval allows Glenmark to enter the market with a generic version of Atovaquone, potentially impacting pricing and market share of existing products.

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — ATOVAQUONE (SUPPL) (FDA). Entity match (atovaquone); Regulatory pathway relevance (nda). Relevant agencies in corpus: FDA, MHRA. While the approval itself does not pose immediate regulatory concerns, it may prompt scrutiny of existing products' compliance and labeling as competition increases.

Key Risks

Elevated medium regulatory exposure for Atovaquone could delay market entry or constrain labeling if agency review intensifies.
Clinical risk from ClinicalTrials.gov (Links Between Inflammation and Cardiometabolic Diseases) could weigh on Atovaquone through efficacy or safety read-through uncertainty if follow-through weakens.

Key Opportunities

Glenmark's generic version may lead to price reductions and increased competition, potentially affecting revenue and market share for existing Atovaquone products.
Upside for Atovaquone may improve if Links Between Inflammation and Cardiometabolic Diseases (ClinicalTrials.gov) delivers favorable follow-through.
Portfolio teams should assess the impact of Glenmark's entry on their own Atovaquone-related products and consider pricing strategies.

What Would Change This Assessment

This becomes more urgent if Monitor Glenmark's launch timeline and market uptake of Atovaquone, as well as responses from competitors.
Timeline shift beyond near term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — ATOVAQUONE (SUPPL)
FDAhigh relevance
Entity match (atovaquone); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — ATOVAQUONE (SUPPL)
FDAhigh relevance
Entity match (atovaquone); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — MALARONE PEDIATRIC (SUPPL)
FDAhigh relevance
Entity match (atovaquone); Regulatory pathway relevance (nda)
FDA document
View source
Clinical trials for medicines: modifying a clinical trial approval
MHRAhigh relevance
Regulatory pathway relevance (approval)
FDA document
View source
FDA AP — DEXTROMETHORPHAN HYDROBROMIDE AND QUINIDINE SULFATE (ORIG)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
Lessons Learned from our Roundtable with Rare Disease Advocates
FDAmedium relevance
Moderate corpus alignment
FDA document
View source

Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopic Dermatitis
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Study of the Spermatic Characteristics of Patients With Fabry Disease
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Links Between Inflammation and Cardiometabolic Diseases
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Connors Protocol for the Management and Use of Stored Human Specimens (Stored Human Specimens)
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Post-Market Clinical Follow-Up (PMCF) Study Evaluating the Safety and Efficacy of Tıpmed™ Revision Hip Prosthesis System
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Core Stability, Functional Capacity, Balance, Strength, and Fatigue in Pediatric Demyelinating Diseases
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

Merck's ENFLONSIA Approved in EU for RSV Prevention in Infants
Humanexa Signalshigh relevance
Sponsor/company relevance (Merck)
Roche receives CE mark for new blood test to detect Alzheimer's pathology: Elecsys® plasma phosphorylated-tau 217 (pTau217)
Rochehigh relevance
Sponsor/company relevance (Roche)
FDA document
View source
Roche receives CE mark for new blood test to detect Alzheimer's pathology: Elecsys® plasma phosphorylated-tau 217 (pTau217)
Rochehigh relevance
Sponsor/company relevance (Roche)
FDA document
View source
Roche's Elecsys® pTau217 Blood Test Receives CE Mark for Alzheimer's Diagnosis
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)
FDA Grants Priority Review for Pfizer's Marstacimab (BLA761369)
Humanexa Signalshigh relevance
Sponsor/company relevance (Pfizer)

Sustained on/off-treatment disease control with abrocitinib for moderate-to-severe atopic dermatitis.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Ginger-based formulations for allergic rhinitis disease: a systematic review and meta-analysis of experimental studies in animals and humans.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
The role of protein palmitoylation in disease pathogenesis and therapeutic innovation.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Research progress of ferroptosis in gynecological diseases.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Progress toward an Epstein-Barr virus vaccine.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Atovaquone
market competitors

Commercial impact

medium

Glenmark's generic version may lead to price reductions and increased competition, potentially affecting revenue and market share for existing Atovaquone products.

Regulatory impact

medium

While the approval itself does not pose immediate regulatory concerns, it may prompt scrutiny of existing products' compliance and labeling as competition increases.

What to watch

Monitor Glenmark's launch timeline and market uptake of Atovaquone, as well as responses from competitors.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.